Viralytics had a single product - Cavatak - and sold for $A500 million, seven times the current IMU market value of $A72 million. IMU has a pipeline of products, in various stages of development.
I'd have thought the best way to maximise shareholder value over the long term is to sell or license drugs/therapies as they progress through at least Stage 2 trials, while continuing development of the rest of the pipeline. Each deal should be able both to fund ongoing research, and might also allow IMU to pay shareholders a juicy special dividend.
While it's easy to start feeling just a bit of excitement, it could easily be a year or more before anything happens that gives the share price a kick along. As with all things biotech, patience is the key.
Leslie Chong Interview 3, page-21
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.9¢ |
Change
0.002(5.41%) |
Mkt cap ! $386.7M | |||
| Open | High | Low | Value | Volume |
| 3.6¢ | 4.0¢ | 3.5¢ | $1.163M | 31.27M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 2275218 | 3.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.9¢ | 196677 | 3 |
View Market Depth
| Last trade - 16.10pm 22/11/2024 (20 minute delay) ? |
| IMU (ASX) Chart |
